Dose Escalation Trial of Anti-IL-20 100mg in Psoriate Pt
ID Number 08-0570Principal Investigator(s)
Carolin T. Penrose
Department(s) or Division(s)
The purpose of this study is to determine the safety and efficacy of the drug Anti-IL-20, as well as its interaction with the body. This drug acts by preventing the activity of IL-20, a factor in psorasis development. The study will target patients who have their first incidence of moderate to severe psorasis present for at least six months. It will include up to eight adult patients, ages 18 - 75, and exclude women of child-bearing age.
Amylynne Frankel, MD
Recruiting Patients: Yes